Lemborexant Treatment of Insomnia Linked to Epilepsy
Recruiting now Phase 3 NCT06262594
Run by University of Manitoba · for 18 and older · All sexes
What this study is about
The goal of this clinical trial is to assess whether Lemborexant can improve sleep in patients with epilepsy.
Who can join (things the study team will check)
✅ You may be able to join if…
- Sleep-related focal epilepsy
- Contraception
🚫 You may not be able to join if…
- Changes in antiseizure medication 1 month before study protocol or during study protocol
- Concomitant medications per SUNRISE1
- Individuals with hepatic impairment
- Female participants who are pregnant or breastfeeding
- Individuals with compromised respiratory function
- Individuals with a history of complex sleep-related behaviour
- Individuals with rare hereditary diseases of galactose intolerance such as galactosemia or glucose-galactose malabsorption
- Individuals with a history of dependence or tolerance - abuse, dependence, rebound insomnia
- Individuals with psychiatric disorders with abnormal thinking and behavioural changes, depression, or suicidal ideation
- Individuals with a diagnosis of narcolepsy
Where this trial is running
- Duke University, Durham, North Carolina, United States
- Health Sciences Centre, Winnipeg, Manitoba, Canada
Who to contact
Marcus C Ng, MD, FRCPC · 204-787-2684 · letoile@umanitoba.ca
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT06262594.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.
Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.